Sotirios Evangelou Sotirios Evangelou

Dr. Sotirios Evangelou Sotirios Evangelou

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Open access
PRPatricia F. Rodriguez-Lozano
Patricia F. Rodriguez-Lozano
AWAnam Waheed
Anam Waheed
SESotirios Evangelou Sotirios Evangelou
Sotirios Evangelou Sotirios Evangelou
MKMárton Kolossváry
Márton Kolossváry
KSKashif Shaikh
Kashif Shaikh
AIAbdul Rahman Ihdayhid
Abdul Rahman Ihdayhid
The integration of computed tomography-derived fractional flow reserve (CT-FFR), utilizing computational fluid dynamics and artificial intelligence (AI) in routine coronary computed tomographic angiography (CCTA), presents a promising approach to enhance evaluations of functional lesion severity. Extensive evidence underscores the diagnostic accuracy, prognostic significance, and clinical relevance of CT-FFR, prompting recent clinical guidelines to recommend its combined use with CCTA for selected individuals with with intermediate stenosis on CCTA and stable or acute chest pain. This manuscript critically examines the existing clinical evidence, evaluates the diagnostic performance, and outlines future perspectives for integrating noninvasive assessments of coronary anatomy and physiology. Furthermore, it serves as a practical guide for medical imaging professionals by addressing common pitfalls and challenges associated with CT-FFR while proposing potential solutions to facilitate its successful implementation in clinical practice.

19 July 2025 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
KSKashif Shaikh
Kashif Shaikh
PRPatricia F. Rodriguez-Lozano
Patricia F. Rodriguez-Lozano
SESotirios Evangelou Sotirios Evangelou
Sotirios Evangelou Sotirios Evangelou
EWEn-Haw Wu
En-Haw Wu
NNNick S. Nurmohamed
Nick S. Nurmohamed
AIAbdul Rahman Ihdayhid
Abdul Rahman Ihdayhid

Verified
Journal Article
Open access
PDF file
GPGeorgios Evaggelos Papadopoulos
Georgios Evaggelos Papadopoulos
INIlias Ninios
Ilias Ninios
SESotirios Evangelou Sotirios Evangelou
Sotirios Evangelou Sotirios Evangelou
AIAndreas Ioannides
Andreas Ioannides
VNVlasis Ninios
Vlasis Ninios
Paravalvular leak (PVL) remains a clinically important complication after surgical or transcatheter valve implantation, presenting predominantly with heart failure (HF) and/or high-shear hemolysis. While redo surgery can be definitive, contemporary candidates frequently carry prohibitive operative risk, positioning transcatheter PVL closure as a key therapeutic alternative. However, available outcome data are largely derived from observational series and registries with heterogeneity in PVL mechanisms, prosthesis types, imaging protocols, and endpoint definitions. Standardized frameworks—such as those proposed by the PVL Academic Research Consortium—support harmonized PVL grading and clinically meaningful composite endpoints that integrate imaging/hemodynamic results with patient-centered outcomes. Across datasets, the most consistent determinant of benefit is residual PVL severity: procedural efficacy is most commonly defined as achieving ≤ mild residual regurgitation without prosthetic leaflet interference, device embolization, or major complications. This review provides a step-by-step, phenotype-driven approach to transcatheter PVL closure, emphasizing multimodality imaging (TEE and cardiac CT, with adjunct CMR and PET when appropriate), access and support planning tailored to valve position, and morphology-matched device selection—often requiring modular multi-device strategies for elongated crescentic channels, particularly in hemolysis-predominant presentations. We also synthesize evidence on complications and bailout management, with a focus on preventable high-severity events (leaflet impingement, embolization, stroke/air, vascular injury, tamponade) and standardized pre-release safety checks. Collectively, contemporary practice supports high implant success in experienced programs, with clinical improvement tightly coupled to procedural endpoint quality and careful Heart Team selection.

Verified
Journal Article
Open access
PDF file
GPGeorgios Evaggelos Papadopoulos
Georgios Evaggelos Papadopoulos
INIlias Ninios
Ilias Ninios
SESotirios Evangelou Sotirios Evangelou
Sotirios Evangelou Sotirios Evangelou
AIAndreas Ioannidis
Andreas Ioannidis
ANAthinodoros Nikitopoulos
Athinodoros Nikitopoulos
VNVlasis Ninios
Vlasis Ninios
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and 30-day and 1-year follow-up outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The postprocedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm2. Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.

14 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
GPGeorgios Evaggelos Papadopoulos
Georgios Evaggelos Papadopoulos
INIlias Ninios
Ilias Ninios
SESotirios Evangelou Sotirios Evangelou
Sotirios Evangelou Sotirios Evangelou
AIAndreas Ioannides
Andreas Ioannides
VNVlasis Ninios
Vlasis Ninios
Paravalvular leak (PVL) remains a clinically important complication after surgical or transcatheter valve implantation, presenting predominantly with heart failure (HF) and/or high-shear hemolysis. While redo surgery can be definitive, contemporary candidates frequently carry prohibitive operative risk, positioning transcatheter PVL closure as a key therapeutic alternative. However, available outcome data are largely derived from observational series and registries with heterogeneity in PVL mechanisms, prosthesis types, imaging protocols, and endpoint definitions. Standardized frameworks—such as those proposed by the PVL Academic Research Consortium—support harmonized PVL grading and clinically meaningful composite endpoints that integrate imaging/hemodynamic results with patient-centered outcomes. Across datasets, the most consistent determinant of benefit is residual PVL severity: procedural efficacy is most commonly defined as achieving ≤mild residual regurgitation without prosthetic leaflet interference, device embolization, or major complications. This review provides a step-by-step, phenotype-driven approach to transcatheter PVL closure, emphasizing multimodality imaging (TEE and cardiac CT, with adjunct CMR and PET when appropriate), access and support planning tailored to valve position, and morphology-matched device selection—often requiring modular multi-device strategies for elongated crescentic channels, particularly in hemolysis-predominant presentations. We also synthesize evidence on complications and bailout management, with a focus on preventable high-severity events (leaflet impingement, embolization, stroke/air, vascular injury, tamponade) and standardized pre-release safety checks. Collectively, contemporary practice supports high implant success in experienced programs, with clinical improvement tightly coupled to procedural endpoint quality and careful Heart Team selection.

7 March 2025 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
GPGeorgios Evaggelos Papadopoulos
Georgios Evaggelos Papadopoulos
INIlias Ninios
Ilias Ninios
ELEleftherios Leptopoulos
Eleftherios Leptopoulos
KPKonstantinos Papazoglou
Konstantinos Papazoglou
KKKonstantinos Konstantinidis
Konstantinos Konstantinidis
VNVlasis Ninios
Vlasis Ninios
Transcatheter aortic valve replacement (TAVR) is a proven treatment for severe aortic stenosis (AS). Transfemoral access is the most prevalent method, achieved either surgically or percutaneously. This study compares in-hospital outcomes and length of stay between surgical cut-down and fully percutaneous approaches. This retrospective, propensity-matched study analyzed medical records of all patients who underwent transfemoral TAVR at our center from January 2019 to December 2023. Outcomes were assessed based on Valve Academic Research Consortium-2 (VARC-2) consensus criteria. 251 TAVR patients (77 propensity score matching pairs) were included (55% female) with a median (IQR) age of 80 (11) years. Surgical cut-down showed fewer vascular complications, bleeding, and transfusions. No death was re-ported in this group. Fewer mean hospitalization days were observed in the total cohort over the years (p< 0.001). This reduction was more pronounced after 2021 when the surgical approach was adopted. Mean hospitalization days were 6.40 ±6.46 for percutaneous and 4.34 ±1.61 for surgical groups (p< 0.001). Surgical cut-down for TAVR femoral access yields superior outcomes and shorter hospital stays compared to fully percutaneous methods.